Patients taking semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have consistently reported reductions in cravings for alcohol, tobacco, and food
Patients switching from a combined oral contraceptive to a progestin-only pill or non-oral method for unrelated reasons do not need to accelerate that switch because of GLP-1 RA co-administration
This same mechanism powers medications like semaglutide (Ozempic/Wegovy), but Retatrutide goes further
It is naturally produced in the body and is found in every cell, playing a vital role in various biological processes
Research areas include: Dual GLP-1 and GIP receptor pharmacology research [1] Body weight and visceral fat reduction models [1] Glucose-driven insulin release and beta cell studies Appetite and satiety pathway research Insulin resistance and type 2 diabetes models Cardiovascular and lipid profile research Studies that separate GLP-1 from GIP signalling How It Works Tirzepatide works by turning on the GLP-1 and GIP receptors at the same time
This is where MeAgain's GLP-1 app fits in, it addresses this by logging medication timing, meals, hydration, and side effects so users and clinicians can spot symptom clusters and make informed adjustments
